Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results